We have previously shown that a monoclonal antibody (MAb) recognizing
the human growth hormone (hGH) antigenic domain left exposed after bin
ding to lactogenic receptors enhanced hGH binding probably through all
osteric effects on the hormone binding site. Since receptors displayin
g different specificities would not recognize exactly the same hGH reg
ion, we explored whether some of our MAb could affect hGH binding to s
omatogenic receptors from rabbit liver and to human liver hGH-specific
receptors. The effect of MAbAE5, AC8 and F11 on hGH binding was measu
red by determining the formation of I-125-MAb:hGH:receptor complexes u
sing two different experimental approaches. Results from procedure A,
which involved the previous binding of the hormone to microsomes befor
e adding I-125-MAb, indicated that the hGH domain defined by epitopes
AE5, AC8 and F11 is uncovered in the various hormone:receptor complexe
s. Procedure B was devised to reveal any alteration in the hGH molecul
e induced by the MAb. In this case preformed I-125-MAb:hGH complexes w
ere added to microsomes. Data showed that I-125-MAb AES:hGH complexes
bound better to the various receptors than I-125-MAb AE5 to hGH:recept
or complexes. On the contrary, hGH previously bound to I-125-MAb AC8 o
r I-125-MAb F11 was less recognized by the receptors than the free hor
mone. Furthermore, binding of MAb AE5 or MAb F11 to hGH 20 K (a natura
l hGH variant lacking residues 32-46) also enhanced its affinity to th
e various receptors whereas MAb AC8 did not inhibit hGH 20 K binding.
Results indicated that MAb recognizing the hGH antigenic area that rem
ains unmasked after binding to different membrane-bound receptors are
able to affect hormone binding site. MAb would induce either positive
or negative allosteric changes in the hormone region involved in its b
inding to lactogenic, somatogenic and hGH-specific receptors.